Excedrin is temporarily stopping production of two drugs meant to treat migraines

It may soon be tough to find two types of Excedrin on shelves.

Excedrin maker GlaxoSmithKline has halted production on caplets and gel tabs of Excedrin Extra Strength and Excedrin Migraine, a spokesperson for the company said in a statement to McClatchy News.

The pause in production comes amid “inconsistencies” in how ingredients are handled.

“Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs,” the statement says. “Based on the available data, GSK believes that the product does not pose a safety risk to consumers.”

The spokesperson said GSK is halting production and distribution as a precaution. Production is expected to start back up shortly.

As pharmacies run out of Excedrin — there’s a shortage in central New York — migraine sufferers say other options don’t cut it, WSYR reported.

“If I was to buy a different brand, it doesn’t even touch it. I haven’t seen it empty like this. It’s kind of scary,” Ashley Eldred told the outlet. “I’ve been suffering for about 10 years. I’ve gone to the doctors. I’ve tried prescription medicines. I had Botox. I’ve tried medical marijuana and I still end up going back to Excedrin.”

GSK urges Excedrin Extra Strength and Excedrin Migraine users to contact their pharmacists to find suitable alternatives, the statement said.